Sie können Operatoren mit Ihrer Suchanfrage kombinieren, um diese noch präziser einzugrenzen. Klicken Sie auf den Suchoperator, um eine Erklärung seiner Funktionsweise anzuzeigen.
Findet Dokumente, in denen beide Begriffe in beliebiger Reihenfolge innerhalb von maximal n Worten zueinander stehen. Empfehlung: Wählen Sie zwischen 15 und 30 als maximale Wortanzahl (z.B. NEAR(hybrid, antrieb, 20)).
Findet Dokumente, in denen der Begriff in Wortvarianten vorkommt, wobei diese VOR, HINTER oder VOR und HINTER dem Suchbegriff anschließen können (z.B., leichtbau*, *leichtbau, *leichtbau*).
Genetic Evaluation of the Patients with Clinically Diagnosed Inborn Errors of Immunity by Whole Exome Sequencing: Results from a Specialized Research Center for Immunodeficiency in Türkiye
Molecular diagnosis of inborn errors of immunity (IEI) plays a critical role in determining patients’ long-term prognosis, treatment options, and genetic counseling. Over the past decade, the broader utilization of next-generation sequencing (NGS) techniques in both research and clinical settings has facilitated the evaluation of a significant proportion of patients for gene variants associated with IEI. In addition to its role in diagnosing known gene defects, the application of high-throughput techniques such as targeted, exome, and genome sequencing has led to the identification of novel disease-causing genes. However, the results obtained from these different methods can vary depending on disease phenotypes or patient characteristics. In this study, we conducted whole-exome sequencing (WES) in a sizable cohort of IEI patients, consisting of 303 individuals from 21 different clinical immunology centers in Türkiye. Our analysis resulted in likely genetic diagnoses for 41.1% of the patients (122 out of 297), revealing 52 novel variants and uncovering potential new IEI genes in six patients. The significance of understanding outcomes across various IEI cohorts cannot be overstated, and we believe that our findings will make a valuable contribution to the existing literature and foster collaborative research between clinicians and basic science researchers.
Aydan Ikinciogulları and Ilhan Tezcan contributed equally to this work.
The original version of this paper was updated due to several errors within the main Table 1 of the manuscript. Four variants were given with different transcript IDs of the same gene. There were also 2 nomenclature errors in the variants of P58 and P117.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Introduction
Inborn errors of immunity or primary immunodeficiencies (PIDs) represent a diverse group of disorders characterized by increased susceptibility to infections, malignancy, allergy, and immune dysregulation [1]. While these diseases occur at a frequency of approximately 1 in 10,000 in the general population, their prevalence is higher in societies with elevated rates of consanguinity, such as Türkiye [2‐4]. The genetic pleiotropy and heterogeneity observed in IEI contribute to the broad range of clinical manifestations associated with these disorders [5]. The majority of IEI cases are monogenic diseases with autosomal recessive inheritance patterns [5]. Therefore, comprehensive genetic diagnosis is vital for effective management of patients with IEI. In the past decade, NGS methods have revolutionized genetic screening, greatly enhancing the diagnostic capabilities for IEI [6]. This progress has led to an unprecedented increase in the identification of genes causing immunodeficiencies, with approximately 500 genetic defects associated with immunodeficiency currently recognized [7].
Founded in 2018 in memory of Can Sucak, who suffered from ZAP70 deficiency, the Candan Bişeyler Foundation (CSCBF) actively supports research in the field of IEI and raises awareness in Türkiye. The “Hacettepe University Can Sucak Research Laboratory for Translational Immunology” is dedicated to providing genetic diagnosis for immunodeficiency patients and conducting advanced functional research in a comprehensive manner throughout the country. This study presents the results of a comprehensive investigation into the genetic diagnosis of an extensive cohort of IEI patients from a specialized immune deficiency research center in Türkiye.
Anzeige
Methods
Study Participants
Patients diagnosed with IEI based on clinical and laboratory characteristics between 2020 and 2023 were included in the study. These patients were recruited from multiple clinical immunology centers in Türkiye. Blood samples were collected from the patients following the guidelines and approval of the local Ethics Committee of Hacettepe University. Informed consent forms were obtained from the participants or their parents. The study's workflow is illustrated in Fig. 1.
Genomic DNA was isolated from peripheral blood samples using a DNA isolation kit (GeneAll). The NGS exome library was prepared utilizing the Illumina Nextera DNA Prep with Enrichment Kit. Sequencing was carried out on the Illumina NextSeq 550 platform, generating 150-bp paired-end reads. Mapping, variant calling, and annotation were performed using SEQ Platform v8 (Genomize). Copy number variation (CNV) analysis was conducted using SEQ Platform as well.
To identify causative variants, we employed a filtering strategy that involved screening all variants identified from the WES data. Our focus was on exonic and splice site variants, excluding synonymous variants, and we specifically looked for rare variants with a minor allele frequency of less than 1% in different strategic gene groups. Initially, we examined rare variants in known IEI genes (approximately 500), followed by potential candidate genes predicted by the human gene connectome [8]. Finally, we assessed variants across the entire set of genes (Supplementary Figure 2A).
Sanger Sequencing
To validate the identified variants, we conducted Sanger sequencing using standard protocols [9].
Anzeige
RT-qPCR
RT-qPCR was utilized to validate the effects of structural variants. Total RNA was isolated from peripheral blood mononuclear cells (PBMCs) obtained from both patients and healthy controls using the NucleoSpin RNA Plus Kit (Macherey-Nagel). Subsequently, cDNA was synthesized using the iScript cDNA synthesis kit (Bio-Rad). RT-qPCR was carried out on the CFX Connect System (Bio-Rad) using the iTaq Universal SYBR Green Supermix (Bio-Rad) [10].
Results
Technical Output of the Sequencing Data
The results of the WES data showed a total number of reads ranging from 21.7 to 77.6 million (median: 46.1) (Supplementary Figure 2B). The average depth of coverage varied between 24.5 and 134.2 (median: 64.1) (Supplementary Figure 2C). The target regions (exons and splice regions) were covered at a depth of 20X from 89.02% to 99.91%, and at a depth of 50X from 68.13% to 99.65% (Supplementary Figure 2D).
Patients
Our study involved a total of 303 individuals who were clinically diagnosed with IEI. These participants were recruited from 21 separate clinical immunology centers and they were selected after assessments with their clinicians. Especially, patients truly exhibited severe phenotypes of immunodeficiency were admitted to the study. However, six patients were excluded from the current analysis as they exhibited potential novel IEI-associated genes, pending further investigation through functional studies. Therefore, the analysis in this study includes 297 patients.
Among the included patients, there were 145 males and 152 females, representing a relatively balanced gender distribution. The age range of the participants varied from three months to 42 years, with a median age of nine years. The majority of the cohort consisted of pediatric patients (n=252), while a smaller subset comprised adult patients (n=45). A notable observation in our study was the high consanguinity rate, with 64.6% (192 out of 297 cases) of patients demonstrating consanguineous relationships within their families. The distribution of clinical diagnoses, classified according to the International Union of Immunological Societies (IUIS) classification, included 27 cases of Severe Combined Immunodeficiency (SCID), 105 cases of Combined Immunodeficiency (CID), 64 cases of Primary Antibody Deficiency (PAD), 49 cases of Primary Immune Regulatory Disorder (PIRD), 22 cases of congenital anomalies affecting phagocyte number/function, 17 cases of disorders of intrinsic and innate immunity, 10 cases of autoinflammatory disorders, and 3 cases of other classified IEI. These other cases potentially involve bone marrow failure or complement deficiencies, as illustrated in Fig. 2A.
Fig. 2
Patient and variant characteristics. A Distribution of the patients based on their clinical diagnosis. B Diagnostic yield of the patients. C Number of the detected variants and their distribution across different IEI genes. D Types of detected variants and their novelty. E Distribution of zygosity. F Number of diagnosis in patient groups
Results of Genetic Diagnosis and the Profile of Disease-Causing Variants
In our cohort, a genetic diagnosis was established in 122 out of the 297 patients examined, with a total of 127 potential genetic variants identified. This yielded a diagnostic rate of 41.1%. Among the 193 patients with consanguineous parents, causative genetic defects were identified in 95 individuals, resulting in a diagnostic rate of 49.7%. On the other hand, among the 106 patients from non-consanguineous parents, 28 individuals (25.7%) received a genetic diagnosis. The diagnostic rate was higher in pediatric patients, with 44.4% (112 out of 252) receiving a genetic diagnosis, compared to the adult group, which had a lower rate of 22% (10 out of 45) (Fig. 2B). Details of all identified genetic variants and their associated clinical features are presented in Table 1, Table 2 and Supplementary Table 3. In addition, variant characteristics including American College of Medical Genetics (ACMG) criteria and pathogenicity prediction scores were given in Supplementary Table 1). Overall, a total of 127 likely causative genetic anomalies were identified across 64 known IEI genes, as depicted in Fig. 2C. Among these genetic variants, 75 had been previously reported in public databases, while 52 were novel findings reported in this study (Fig. 2D). The variants consisted of 92 homozygous, 27 heterozygous, and 8 hemizygous mutations (Fig. 2E). The spectrum of variant types included 69 missense mutations, 24 nonsense mutations, 22 insertion/deletions (indels), 9 essential splice site variations, and 3 copy number variations (Figure 2D). CNV analysis was performed on 57 subjects using a strategy that incorporated samples with comparable mean read depths. The implications of the CNVs were validated through capillary sequencing or quantitative PCR (qPCR). The causality of monoallelic variants was evaluated based on clinical and laboratory features of the patients, literature associations, or different functional analyses (Supplementary Table 2). The diagnostic rates across different disease categories were as follows: Severe Combined Immunodeficiency (SCID) had a diagnostic rate of 100%, congenital anomalies affecting phagocyte number/function at 68.1%, autoinflammatory disorders at 50%, Primary Immune Regulatory Disorder (PIRD) at 46.9%, intrinsic and innate immunity defects at 41.1%, Combined Immunodeficiency (CID) at 32.3%, other forms of IEI at 33.3%, and Primary Antibody Deficiency (PAD) at 15.6%, and (Fig. 2F).
SCID Severe combined immunodeficiency, CID Combined immunodeficiency, PAD Primary antibody deficiency, CVID Common variable immunodeficiency, PIRD Primary immune regulation disorder, m months, M Male, F Female, Consan Consanguinity, Hom Homozygous, Het Heterozygous, Hem Hemizygous, CNV Copy number variation
Table 2
Clinical features of the patients associated with detected gene defects
Patient no
Clinical diagnosis (IUIS classification)
Gene
Variant
Associated features of the patients
P1
Innate immune defect
CARD9
c.883C>T p.Gln295Ter
Invasive fungal infection, HSM, dermatitis, elevated IgG and IgE
P2
CID
RFXANK
c.634C>T p.Arg212Ter
Failure to thrive, respiratory and gastrointestinal infections, low CD4+ T cells
Chronic diarrhea, elevated hepatic transaminases, failure to thrive, agammaglobulinemia
P69
PIRD
UNC13D
c.1082del p.Tyr361SerfsTer43
HLH, pancytopenia
P70
PIRD
FAS
c.361C>T p.Arg121Trp
Splenomegaly, lymphadenopathy, ITP
P71
PIRD
PRF1
c.1122G>A p.Trp374Ter
HLH, HSM, reduced NK cells
P72
CID
DOCK8
c.5831C>T p.Pro1944Leu
Human papillomavirus (HPV) infections, recurrent sinopulmonary and gastrointestinal infections, elevated IgE, reduced naive and increased memory CD8+ T cells
P73
CID
DOCK8
c.5831C>T p.Pro1944Leu
Recurrent sinopulmonary and gastrointestinal infections, severe atopy, eosinophilia, elevated IgE, reduced naive and increased memory CD8+ T cells
P74
PIRD
CTLA4
c.151C>T p.Arg51Ter
Lymphadenopathy, lymphopenia, hypogammaglobulinemia, reduced switched memory B cells
P75
Phagocyte defect
HAX1
c.130_131insA p.Trp44Ter
Recurrent perianal abscess, neutropenia
P76
CID
PIK3CG
c.2159A>G p.Tyr720Cys
Severe atopic dermatitis, multiple food allergies, eosinophilia, hypogammaglobulinemia
P77
CID
MALT1
c.1133T>G p.Phe378Cys
Failure to thrive, moniliasis, necrotizing skin lesions, lymphoproliferation
Recurrent pulmonary infections, bronchiectasis, CMC, nail dystrophia, severe growth retardation, hypothyroidism, hypergammaglobulinemia, CD4+ T cel lymphopenia
P104
CID
IL6ST
c.2093C>A p.Ala698Glu
Recurrent pulmonary infections, bronchiectasis, severe eczema, hypogammaglobulinemia, elevated IgE, lymphopenia
P105
Innate immune defect
IL12RB1
c.637C>T p.Arg213Trp
Severe pulmonary tuberculosis, vasculitis, recurrent arthritis
P106
CID
DOCK8
c.5766G>A p.Met1922Ile
Severe eczema, multiple food allergies, recurrent infections, elevated IgE, lymphopenia
Advancements in NGS, with WES at the forefront, have been instrumental in the diagnostic processes of IEI by pinpointing causative genetic aberrations [72]. Genetic diagnosis now routinely assists in the delineation of IEI, underscoring its significance in the strategic management of patient treatments. Literature suggests a wide-ranging diagnostic yield for targeted and exome sequencing, from 10% to 70%, across various IEI patient groups [23, 58, 68, 73‐79] . In this study, out of the 127 causative genetic defects in 122 patients, we identified 52 novel IEI-causing variants. We also discovered novel and very rare gene variants in NFATC2, CHUK, and PIK3CG genes, which have limited reported cases in the literature [80‐83].
Among the 297 patients evaluated, a genetic etiology was confirmed in 122 individuals, resulting in a diagnostic yield of 41.1%. Diagnostic success exhibited pronounced variation among the different IEI subtypes: cases of SCID reached a 100% genetic identification rate, whereas CID and PID manifested lower diagnostic rates of 31% and 45%, respectively. Within the PAD cohort, genetic causality was determined in a mere 15.6% of cases (10 patients). This notably diminished diagnostic yield in Primary Antibody Deficiencies is in concordance with prior regional studies conducted by Fırtına S et al. [84]. In contrast, patients with probable Mendelian susceptibility to mycobacterial diseases and chronic granulomatous disease (CGD) demonstrated significantly higher diagnostic rates, with near-complete success in CGD patients.
The discrepancies in diagnostic success among IEI subtypes are primarily attributed to the complex nature of these disorders rather than limitations of WES. Factors such as the specific type of immunodeficiency, diverse clinical presentations, patient medical histories, and environmental influences affect the probability of achieving a genetic diagnosis [72]. Other factors include variable gene penetrance, the distinction between monogenic and polygenic influences, and various environmental considerations such as pathogenic exposures and age at presentation [85, 86]. Consanguinity plays a significant role in genetic diagnosis, as most IEI cases have autosomal recessive inheritance. Consanguineous populations or those from isolated regions with distinct phenotypes have reported higher diagnostic yields [87]. In our study, the consanguinity rate was 64.6%, and a diagnosis was made in 49.7% of those cases. We found 27 heterozygous variants in 21 unrelated patients, which can provide insights into the impact of heterozygous variants on protein function and aid in the search for novel IEI genes.
Anzeige
Currently, approximately 500 genetic etiologies leading to IEI are known [7]. Although the use of NGS, particularly WES, is increasing, it has limitations. Exome sequencing focuses on coding regions and essential splice sites, making it challenging to detect structural variations [72] and the use of short-read sequencing as in our study makes it difficult to map reads to repeated sequences, and pseudogenes [88]. Long-read sequencing (LRS) technologies both for exome or genome, have the capacity to enhance the detection of genetic variations and regions that are challenging to analyze with existing short-read NGS techniques [88‐90]. However, the cost and complexity of analyzing large datasets pose challenges for WGS. In our study, we only identified three structural variants in 57 patients. Nevertheless, studies have shown the effectiveness of WGS in detecting both CNVs and coding variants [91, 92]. Reducing the cost of WGS and developing user-friendly bioinformatic tools may make it a routine diagnostic approach for IEI screening.
In conclusion, our findings highlight the limited success of WES in the genetic investigation of presumed IEI. The prospective adoption of WGS could enhance diagnostic yields, potentially surpassing WES in clinical examinations. With our substantial study cohort and diverse clinical presentations, the genetic variations we have identified will significantly contribute to the diagnosis of future IEI cases and guide the development of optimized NGS panels for these conditions.
Acknowledgements
We express our gratitude to the “Can Sucak Candan Biseyler” Foundation (CSCBF) for their valuable support and contributions throughout this study. The CSCBF was established in 2018 to honor the memory of Can Sucak, who tragically passed away due to complications of primary immunodeficiency. The foundation actively supports research in the field of primary immunodeficiency and raises awareness about this condition. Additionally, we would like to acknowledge The Hospital Research Foundation (THRF) for their support of GC.
Declarations
Consent to Participate
Informed consent was obtained from all individual participants who were included in the study.
Anzeige
Consent for Publication
The manuscript does not contain any personal data of individual participants.
Conflict of Interests
The authors declare no competing interests.
Ethics Approval
This study was conducted in accordance with the principles outlined in the Declaration of Helsinki. Approval for the study was obtained from the local Ethics Committee of Hacettepe University (Approval number: GO 20/407).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Genetic Evaluation of the Patients with Clinically Diagnosed Inborn Errors of Immunity by Whole Exome Sequencing: Results from a Specialized Research Center for Immunodeficiency in Türkiye
Verfasst von
Baran Erman
Umran Aba
Canberk Ipsir
Damla Pehlivan
Caner Aytekin
Gökhan Cildir
Begum Cicek
Ceren Bozkurt
Sidem Tekeoglu
Melisa Kaya
Cigdem Aydogmus
Funda Cipe
Gulsan Sucak
Sevgi Bilgic Eltan
Ahmet Ozen
Safa Barıs
Elif Karakoc-Aydiner
Ayca Kıykım
Betul Karaatmaca
Hulya Kose
Dilara Fatma Kocacık Uygun
Fatih Celmeli
Tugba Arikoglu
Dilek Ozcan
Ozlem Keskin
Elif Arık
Elif Soyak Aytekin
Mahmut Cesur
Ercan Kucukosmanoglu
Mehmet Kılıc
Mutlu Yuksek
Zafer Bıcakcı
Saliha Esenboga
Deniz Çagdaş Ayvaz
Asena Pınar Sefer
Sukrü Nail Guner
Sevgi Keles
Ismail Reisli
Ugur Musabak
Nazlı Deveci Demirbas
Sule Haskologlu
Sara Sebnem Kilic
Ayse Metin
Figen Dogu
Aydan Ikinciogulları
Ilhan Tezcan
Notarangelo LD, Bacchetta R, Casanova JL, Su HC. Human inborn errors of immunity: An expanding universe. Sci Immunol. 2020;5(49)
2.
Eldeniz FC, Gul Y, Yorulmaz A, Guner SN, Keles S, Reisli I. Evaluation of the 10 Warning Signs in Primary and Secondary Immunodeficient Patients. Front Immunol. 2022;13:900055.PubMedPubMedCentral
3.
Meyts I, Bousfiha A, Duff C, Singh S, Lau YL, Condino-Neto A, et al. Primary Immunodeficiencies: A Decade of Progress and a Promising Future. Front Immunol. 2020;11:625753.PubMed
4.
Sanal O, Tezcan I. Thirty years of primary immunodeficiencies in Turkey. Ann N Y Acad Sci. 2011;1238:15–23.PubMed
5.
Conley ME, Casanova JL. Discovery of single-gene inborn errors of immunity by next generation sequencing. Curr Opin Immunol. 2014;30:17–23.PubMed
6.
Vorsteveld EE, Hoischen A, van der Made CI. Next-Generation Sequencing in the Field of Primary Immunodeficiencies: Current Yield, Challenges, and Future Perspectives. Clin Rev Allergy Immunol. 2021;61(2):212–25.PubMedPubMedCentral
7.
Tangye SG, Al-Herz W, Bousfiha A, Cunningham-Rundles C, Franco JL, Holland SM, et al. Human Inborn Errors of Immunity: 2022 Update on the Classification from the International Union of Immunological Societies Expert Committee. J Clin Immunol. 2022;42(7):1473–507.PubMedPubMedCentral
8.
Itan Y, Casanova JL. Novel primary immunodeficiency candidate genes predicted by the human gene connectome. Front Immunol. 2015;6:142.PubMedPubMedCentral
9.
Halacli SO, Ayvaz DC, Sun-Tan C, Erman B, Uz E, Yilmaz DY, et al. STK4 (MST1) deficiency in two siblings with autoimmune cytopenias: A novel mutation. Clin Immunol. 2015;161(2):316–23.PubMed
10.
Aba Ü, Maslak IC, Ipsir C, Pehlivan D, Warnock NI, Tumes DJ, et al. A Novel Homozygous Germline Mutation in Transferrin Receptor 1 (TfR1) Leads to Combined Immunodeficiency and Provides New Insights into Iron-Immunity Axis. J Clin Immunol. 2024;44(2)
11.
Erman B, Firtina S, Aksoy BA, Aydogdu S, Genc GE, Dogan O, et al. Invasive Saprochaete capitata Infection in a Patient with Autosomal Recessive CARD9 Deficiency and a Review of the Literature. J Clin Immunol. 2020;40(3):466–74.PubMed
12.
Erman B, Cipe F. Genetic Screening of the Patients with Primary Immunodeficiency by Whole-Exome Sequencing. Pediatr Allergy Immunol Pulmonol. 2020;33(1):19–24.PubMedPubMedCentral
13.
Erman B, Firtina S, Fisgin T, Bozkurt C, Cipe FE. Biallelic Form of a Known CD3E Mutation in a Patient with Severe Combined Immunodeficiency. J Clin Immunol. 2020;40(3):539–42.PubMed
14.
Ghosh S, Kostel Bal S, Edwards ESJ, Pillay B, Jimenez Heredia R, Erol Cipe F, et al. Extended clinical and immunological phenotype and transplant outcome in CD27 and CD70 deficiency. Blood. 2020;136(23):2638–55.PubMedPubMedCentral
15.
Béziat V, Li J, Lin JX, Ma CS, Li P, Bousfiha A, et al. A recessive form of hyper-IgE syndrome by disruption of ZNF341-dependent STAT3 transcription and activity. Sci Immunol. 2018;3(24)
16.
Meshaal SS, El Hawary RE, Abd Elaziz DS, Eldash A, Alkady R, Lotfy S, et al. Phenotypical heterogeneity in RAG-deficient patients from a highly consanguineous population. Clin Exp Immunol. 2019;195(2):202–12.PubMed
17.
Tabori U, Mark Z, Amariglio N, Etzioni A, Golan H, Biloray B, et al. Detection of RAG mutations and prenatal diagnosis in families presenting with either T-B severe combined immunodeficiency or Omenn's syndrome. Clinical Genetics. 2004;65(4):322–6.PubMed
18.
Castigli E, Wilson SA, Garibyan L, Rachid R, Bonilla F, Schneider L, Geha RS. TACI is mutant in common variable immunodeficiency and IgA deficiency. Nat Genet. 2005;37(8):829–34.PubMed
19.
Salzer U, Chapel HM, Webster ADB, Pan-Hammarström Q, Schmitt-Graeff A, Schlesier M, et al. Mutations in encoding TACI are associated with common variable immunodeficiency in humans. Nat Genet. 2005;37(8):820–8.PubMed
20.
Köker MY, van Leeuwen K, de Boer M, Çelmeli F, Metin A, Özgür TT, et al. Six different mutations including three novel mutations in ten families from Turkey, resulting in autosomal recessive chronic granulomatous disease. Eur J Clin Invest. 2009;39(4):311–9.PubMed
21.
Rae J, Noack D, Heyworth PG, Ellis BA, Curnutte JT, Cross AR. Molecular analysis of 9 new families with chronic granulomatous disease caused by mutations in, the gene encoding p22. Blood. 2000;96(3):1106–12.PubMed
22.
Sefer AP, Abolhassani H, Ober F, Kayaoglu B, Bilgic Eltan S, Kara A, et al. Expanding the Clinical and Immunological Phenotypes and Natural History of MALT1 Deficiency. J Clin Immunol. 2022;42(3):634–52.PubMed
23.
Rae W, Ward D, Mattocks C, Pengelly RJ, Eren E, Patel SV, et al. Clinical efficacy of a next-generation sequencing gene panel for primary immunodeficiency diagnostics. Clin Genet. 2018;93(3):647–55.PubMed
24.
Egg D, Rump IC, Mitsuiki N, Rojas-Restrepo J, Maccari ME, Schwab C, et al. Therapeutic options for CTLA-4 insufficiency. J Allergy Clin Immunol. 2022;149(2):736–46.PubMed
25.
Hoshino A, Tanita K, Kanda K, Imadome KI, Shikama Y, Yasumi T, et al. High frequencies of asymptomatic Epstein-Barr virus viremia in affected and unaffected individuals with CTLA4 mutations. Clin Immunol. 2018;195:45–8.PubMed
26.
Schwab C, Gabrysch A, Olbrich P, Patino V, Warnatz K, Wolff D, et al. Phenotype, penetrance, and treatment of 133 cytotoxic T-lymphocyte antigen 4-insufficient subjects. J Allergy Clin Immunol. 2018;142(6):1932–46.PubMedPubMedCentral
27.
Minegishi Y, Coustan-Smith E, Wang YH, Cooper MD, Campana D, Conley ME. Mutations in the human λ5/14.1 gene result in B cell deficiency and agammaglobulinemia. J Exp Med. 1998;187(1):71–7.PubMedPubMedCentral
28.
Kulkarni M, Hule G, de Boer M, van Leeuwen K, Kambli P, Aluri J, et al. Approach to Molecular Diagnosis of Chronic Granulomatous Disease (CGD): an Experience from a Large Cohort of 90 Indian Patients. J Clin Immunol. 2018;38(8):898–916.PubMed
29.
Noack D, Rae J, Cross AR, Muñoz J, Salmen S, Mendoza JA, et al. Autosomal recessive chronic granulomatous disease caused by novel mutations in , the gene encoding the p67-component of phagocyte NADPH oxidase. Hum Genet. 1999;105(5):460–7.PubMed
30.
de Beaucoudrey L, Samarina A, Bustamante J, Cobat A, Boisson-Dupuis S, Feinberg J, et al. Revisiting human IL-12Rbeta1 deficiency: a survey of 141 patients from 30 countries. Medicine (Baltimore). 2010;89(6):381–402.PubMedPubMedCentral
31.
Hatipoglu N, Guvenc BH, Deswarte C, Koksalan K, Boisson-Dupuis S, Casanova JL, Bustamante J. Inherited IL-12Rbeta1 Deficiency in a Child With BCG Adenitis and Oral Candidiasis: A Case Report. Pediatrics. 2017;140(5)
32.
Carmona-Rivera C, Khaznadar SS, Shwin KW, Irizarry-Caro JA, O'Neil LJ, Liu Y, et al. Deficiency of adenosine deaminase 2 triggers adenosine-mediated NETosis and TNF production in patients with DADA2. Blood. 2019;134(4):395–406.PubMedPubMedCentral
33.
Hashem H, Kumar AR, Muller I, Babor F, Bredius R, Dalal J, et al. Hematopoietic stem cell transplantation rescues the hematological, immunological, and vascular phenotype in DADA2. Blood. 2017;130(24):2682–8.PubMedPubMedCentral
34.
Hashem H, Vatsayan A, Gupta A, Nagle K, Hershfield M, Dalal J. Successful reduced intensity hematopoietic cell transplant in a patient with deficiency of adenosine deaminase 2. Bone Marrow Transplant. 2017;52(11):1575–6.PubMed
35.
Asilsoy S, Bilgili G, Turul T, Dizdarer C, Kalkan S, Yasli H, et al. Interleukin-12/-23 receptor beta 1 deficiency in an infant with draining BCG lymphadenitis. Pediatr Int. 2009;51(2):310–2.PubMed
36.
Fieschi C, Dupuis S, Catherinot E, Feinberg J, Bustamante J, Breiman A, et al. Low penetrance, broad resistance, and favorable outcome of interleukin 12 receptor beta1 deficiency: medical and immunological implications. J Exp Med. 2003;197(4):527–35.PubMedPubMedCentral
37.
Park AY, Leney-Greene M, Lynberg M, Gabrielski JQ, Xu X, Schwarz B, et al. GIMAP5 deficiency reveals a mammalian ceramide-driven longevity assurance pathway. Nat Immunol. 2024;25(2):282–93.PubMed
38.
Bettinardi A, Brugnoni D, Quiros-Roldan E, Malagoli A, La Grutta S, Correra A, Notarangelo LD. Missense mutations in the Fas gene resulting in autoimmune lymphoproliferative syndrome: a molecular and immunological analysis. Blood. 1997;89(3):902–9.PubMed
39.
Balta G, Okur H, Unal S, Yarali N, Gunes AM, Unal S, et al. Assessment of clinical and laboratory presentations of familial hemophagocytic lymphohistiocytosis patients with homozygous W374X mutation. Leuk Res. 2010;34(8):1012–7.PubMed
40.
Zur Stadt U, Beutel K, Kolberg S, Schneppenheim R, Kabisch H, Janka G, Hennies HC. Mutation spectrum in children with primary hemophagocytic lymphohistiocytosis: molecular and functional analyses of PRF1, UNC13D, STX11, and RAB27A. Hum Mutat. 2006;27(1):62–8.PubMed
41.
Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, et al. Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science. 2014;345(6204):1623–7.PubMedPubMedCentral
42.
Germeshausen M, Grudzien M, Zeidler C, Abdollahpour H, Yetgin S, Rezaei N, et al. Novel HAX1 mutations in patients with severe congenital neutropenia reveal isoform-dependent genotype-phenotype associations. Blood. 2008;111(10):4954–7.PubMed
43.
Klein C, Grudzien M, Appaswamy G, Germeshausen M, Sandrock I, Schaffer AA, et al. HAX1 deficiency causes autosomal recessive severe congenital neutropenia (Kostmann disease). Nat Genet. 2007;39(1):86–92.PubMed
44.
Briggs TA, Rice GI, Daly S, Urquhart J, Gornall H, Bader-Meunier B, et al. Tartrate-resistant acid phosphatase deficiency causes a bone dysplasia with autoimmunity and a type I interferon expression signature. Nat Genet. 2011;43(2):127–31.PubMed
45.
Stray-Pedersen A, Backe PH, Sorte HS, Morkrid L, Chokshi NY, Erichsen HC, et al. PGM3 mutations cause a congenital disorder of glycosylation with severe immunodeficiency and skeletal dysplasia. Am J Hum Genet. 2014;95(1):96–107.PubMedPubMedCentral
46.
Rowe JH, Delmonte OM, Keles S, Stadinski BD, Dobbs AK, Henderson LA, et al. Patients with CD3G mutations reveal a role for human CD3gamma in T(reg) diversity and suppressive function. Blood. 2018;131(21):2335–44.PubMedPubMedCentral
47.
Teimourian S, Zomorodian E, Badalzadeh M, Pouya A, Kannengiesser C, Mansouri D, et al. Characterization of six novel mutations in CYBA: the gene causing autosomal recessive chronic granulomatous disease. Br J Haematol. 2008;141(6):848–51.PubMed
48.
Cetica V, Hackmann Y, Grieve S, Sieni E, Ciambotti B, Coniglio ML, et al. Patients with Griscelli syndrome and normal pigmentation identify RAB27A mutations that selectively disrupt MUNC13-4 binding. J Allergy Clin Immunol. 2015;135(5):1310–8 e1.PubMedPubMedCentral
49.
Mamishi S, Modarressi MH, Pourakbari B, Tamizifar B, Mahjoub F, Fahimzad A, et al. Analysis of RAB27A gene in griscelli syndrome type 2: novel mutations including a deletion hotspot. J Clin Immunol. 2008;28(4):384–9.PubMed
50.
Sarper N, Ipek IO, Ceran O, Karaman S, Bozaykut A, Inan S. A rare syndrome in the differential diagnosis of hepatosplenomegaly and pancytopenia: report of identical twins with Griscelli disease. Ann Trop Paediatr. 2003;23(1):69–73.PubMed
51.
Sepulveda FE, Debeurme F, Menasche G, Kurowska M, Cote M, Pachlopnik Schmid J, et al. Distinct severity of HLH in both human and murine mutants with complete loss of cytotoxic effector PRF1, RAB27A, and STX11. Blood. 2013;121(4):595–603.PubMed
52.
Cagdas D, Halacli SO, Tan C, Lo B, Cetinkaya PG, Esenboga S, et al. A Spectrum of Clinical Findings from ALPS to CVID: Several Novel LRBA Defects. J Clin Immunol. 2019;39(7):726–38.PubMedPubMedCentral
53.
Gamez-Diaz L, August D, Stepensky P, Revel-Vilk S, Seidel MG, Noriko M, et al. The extended phenotype of LPS-responsive beige-like anchor protein (LRBA) deficiency. J Allergy Clin Immunol. 2016;137(1):223–30.PubMed
54.
Lo B, Zhang K, Lu W, Zheng L, Zhang Q, Kanellopoulou C, et al. AUTOIMMUNE DISEASE. Patients with LRBA deficiency show CTLA4 loss and immune dysregulation responsive to abatacept therapy. Science. 2015;349(6246):436–40.PubMed
55.
Esenboga S, Akal C, Karaatmaca B, Erman B, Dogan S, Orhan D, et al. Two siblings with PRKDC defect who presented with cutaneous granulomas and review of the literature. Clin Immunol. 2018;197:1–5.PubMed
56.
Mathieu AL, Verronese E, Rice GI, Fouyssac F, Bertrand Y, Picard C, et al. PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity. J Allergy Clin Immunol. 2015;135(6):1578–88 e5.PubMedPubMedCentral
57.
van der Burg M, Ijspeert H, Verkaik NS, Turul T, Wiegant WW, Morotomi-Yano K, et al. A DNA-PKcs mutation in a radiosensitive T-B- SCID patient inhibits Artemis activation and nonhomologous end-joining. J Clin Invest. 2009;119(1):91–8.PubMed
58.
Yu H, Zhang VW, Stray-Pedersen A, Hanson IC, Forbes LR, de la Morena MT, et al. Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing. J Allergy Clin Immunol. 2016;138(4):1142–51 e2.PubMed
59.
Walter JE, Rosen LB, Csomos K, Rosenberg JM, Mathew D, Keszei M, et al. Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency. J Clin Invest. 2015;125(11):4135–48.PubMedPubMedCentral
60.
Coulter TI, Chandra A, Bacon CM, Babar J, Curtis J, Screaton N, et al. Clinical spectrum and features of activated phosphoinositide 3-kinase delta syndrome: A large patient cohort study. J Allergy Clin Immunol. 2017;139(2):597–606 e4.PubMedPubMedCentral
61.
Lucas CL, Kuehn HS, Zhao F, Niemela JE, Deenick EK, Palendira U, et al. Dominant-activating germline mutations in the gene encoding the PI(3)K catalytic subunit p110delta result in T cell senescence and human immunodeficiency. Nat Immunol. 2014;15(1):88–97.PubMed
62.
Altare F, Ensser A, Breiman A, Reichenbach J, Baghdadi JE, Fischer A, et al. Interleukin-12 receptor beta1 deficiency in a patient with abdominal tuberculosis. J Infect Dis. 2001;184(2):231–6.PubMed
63.
Sakai T, Matsuoka M, Aoki M, Nosaka K, Mitsuya H. Missense mutation of the interleukin-12 receptor beta1 chain-encoding gene is associated with impaired immunity against Mycobacterium avium complex infection. Blood. 2001;97(9):2688–94.PubMed
64.
Adams SP, Wilson M, Harb E, Fairbanks L, Xu-Bayford J, Brown L, et al. Spectrum of mutations in a cohort of UK patients with ADA deficient SCID: Segregation of genotypes with specific ethnicities. Clin Immunol. 2015;161(2):174–9.PubMed
65.
Lee PP, Chan KW, Chen TX, Jiang LP, Wang XC, Zeng HS, et al. Molecular diagnosis of severe combined immunodeficiency--identification of IL2RG, JAK3, IL7R, DCLRE1C, RAG1, and RAG2 mutations in a cohort of Chinese and Southeast Asian children. J Clin Immunol. 2011;31(2):281–96.PubMed
66.
Reiff A, Bassuk AG, Church JA, Campbell E, Bing X, Ferguson PJ. Exome sequencing reveals RAG1 mutations in a child with autoimmunity and sterile chronic multifocal osteomyelitis evolving into disseminated granulomatous disease. J Clin Immunol. 2013;33(8):1289–92.PubMedPubMedCentral
67.
Zhang ZY, Zhao XD, Jiang LP, Liu EM, Cui YX, Wang M, et al. Clinical characteristics and molecular analysis of three Chinese children with Omenn syndrome. Pediatr Allergy Immunol. 2011;22(5):482–7.PubMed
68.
Simon AJ, Golan AC, Lev A, Stauber T, Barel O, Somekh I, et al. Whole exome sequencing (WES) approach for diagnosing primary immunodeficiencies (PIDs) in a highly consanguineous community. Clin Immunol. 2020;214:108376.PubMed
69.
Niemela J, Kuehn HS, Kelly C, Zhang M, Davies J, Melendez J, et al. Caspase-8 Deficiency Presenting as Late-Onset Multi-Organ Lymphocytic Infiltration with Granulomas in two Adult Siblings. J Clin Immunol. 2015;35(4):348–55.PubMedPubMedCentral
70.
Schuetz C, Huck K, Gudowius S, Megahed M, Feyen O, Hubner B, et al. An immunodeficiency disease with RAG mutations and granulomas. N Engl J Med. 2008;358(19):2030–8.PubMed
71.
Villa A, Santagata S, Bozzi F, Giliani S, Frattini A, Imberti L, et al. Partial V(D)J recombination activity leads to Omenn syndrome. Cell. 1998;93(5):885–96.PubMed
72.
Picard C, Fischer A. Contribution of high-throughput DNA sequencing to the study of primary immunodeficiencies. Eur J Immunol. 2014;44(10):2854–61.PubMed
73.
Al-Mousa H, Abouelhoda M, Monies DM, Al-Tassan N, Al-Ghonaium A, Al-Saud B, et al. Unbiased targeted next-generation sequencing molecular approach for primary immunodeficiency diseases. J Allergy Clin Immunol. 2016;137(6):1780–7.PubMed
74.
Bisgin A, Boga I, Yilmaz M, Bingol G, Altintas D. The Utility of Next-Generation Sequencing for Primary Immunodeficiency Disorders: Experience from a Clinical Diagnostic Laboratory. Biomed Res Int. 2018;2018:9647253.PubMedPubMedCentral
75.
Erman B, Bilic I, Hirschmugl T, Salzer E, Boztug H, Sanal O, et al. Investigation of Genetic Defects in Severe Combined Immunodeficiency Patients from Turkey by Targeted Sequencing. Scand J Immunol. 2017;85(3):227–34.PubMed
76.
Kojima D, Wang X, Muramatsu H, Okuno Y, Nishio N, Hama A, et al. Application of extensively targeted next-generation sequencing for the diagnosis of primary immunodeficiencies. J Allergy Clin Immunol. 2016;138(1):303–5 e3.PubMed
77.
Moens LN, Falk-Sorqvist E, Asplund AC, Bernatowska E, Smith CI, Nilsson M. Diagnostics of primary immunodeficiency diseases: a sequencing capture approach. PLoS One. 2014;9(12):e114901.PubMedPubMedCentral
78.
Nijman IJ, van Montfrans JM, Hoogstraat M, Boes ML, van de Corput L, Renner ED, et al. Targeted next-generation sequencing: a novel diagnostic tool for primary immunodeficiencies. J Allergy Clin Immunol. 2014;133(2):529–34.PubMed
79.
Okano T, Imai K, Naruto T, Okada S, Yamashita M, Yeh TW, et al. Whole-Exome Sequencing-Based Approach for Germline Mutations in Patients with Inborn Errors of Immunity. J Clin Immunol. 2020;40(5):729–40.PubMed
80.
Bainter W, Lougaris V, Wallace JG, Badran Y, Hoyos-Bachiloglu R, Peters Z, et al. Combined immunodeficiency with autoimmunity caused by a homozygous missense mutation in inhibitor of nuclear factor ?B kinase alpha (IKKalpha). Sci Immunol. 2021;6(63):eabf6723.PubMedPubMedCentral
81.
Sharma M, Fu MP, Lu HY, Sharma AA, Modi BP, Michalski C, et al. Human complete NFAT1 deficiency causes a triad of joint contractures, osteochondromas, and B-cell malignancy. Blood. 2022;140(17):1858–74.PubMed
82.
Takeda AJ, Maher TJ, Zhang Y, Lanahan SM, Bucklin ML, Compton SR, et al. Human PI3Kgamma deficiency and its microbiota-dependent mouse model reveal immunodeficiency and tissue immunopathology. Nat Commun. 2019;10(1):4364.PubMedPubMedCentral
83.
Thian M, Hoeger B, Kamnev A, Poyer F, Kostel Bal S, Caldera M, et al. Germline biallelic PIK3CG mutations in a multifaceted immunodeficiency with immune dysregulation. Haematologica. 2020;105(10):e488.PubMed
84.
Firtina S, Ng YY, Ng OH, Kiykim A, Ozek EY, Kara M, et al. Primary antibody deficiencies in Turkey: molecular and clinical aspects. Immunol Res. 2022;70(1):44–55.PubMed
85.
Edwards ESJ, Bosco JJ, Ojaimi S, O'Hehir RE, van Zelm MC. Beyond monogenetic rare variants: tackling the low rate of genetic diagnoses in predominantly antibody deficiency. Cell Mol Immunol. 2021;18(3):588–603.PubMed
86.
Rojas-Restrepo J, Caballero-Oteyza A, Huebscher K, Haberstroh H, Fliegauf M, Keller B, et al. Establishing the Molecular Diagnoses in a Cohort of 291 Patients With Predominantly Antibody Deficiency by Targeted Next-Generation Sequencing: Experience From a Monocentric Study. Front Immunol. 2021;12:786516.PubMedPubMedCentral
87.
Abolhassani H, Chou J, Bainter W, Platt CD, Tavassoli M, Momen T, et al. Clinical, immunologic, and genetic spectrum of 696 patients with combined immunodeficiency. J Allergy Clin Immunol. 2018;141(4):1450–8.PubMed
88.
Mantere T, Kersten S, Hoischen A. Long-Read Sequencing Emerging in Medical Genetics. Front Genet. 2019;10:426.PubMedPubMedCentral
89.
Sanford Kobayashi E, Batalov S, Wenger AM, Lambert C, Dhillon H, Hall RJ, et al. Approaches to long-read sequencing in a clinical setting to improve diagnostic rate. Sci Rep. 2022;12(1):16945.PubMedPubMedCentral
90.
Troskie RL, Jafrani Y, Mercer TR, Ewing AD, Faulkner GJ, Cheetham SW. Long-read cDNA sequencing identifies functional pseudogenes in the human transcriptome. Genome Biol. 2021;22(1):146.PubMedPubMedCentral
91.
Belkadi A, Bolze A, Itan Y, Cobat A, Vincent QB, Antipenko A, et al. Whole-genome sequencing is more powerful than whole-exome sequencing for detecting exome variants. Proc Natl Acad Sci U S A. 2015;112(17):5473–8.PubMedPubMedCentral
92.
Thaventhiran JED, Lango Allen H, Burren OS, Rae W, Greene D, Staples E, et al. Whole-genome sequencing of a sporadic primary immunodeficiency cohort. Nature. 2020;583(7814):90–5.PubMedPubMedCentral
Erhalten Menschen mit multiplem Myelom bereits nach dem ersten Versagen einer Lenalidomid-Behandlung eine CAR-T-Zell-Therapie gegen BCMA, wird die Sterberate im Vergleich zu einer Standardbehandlung um 45% reduziert. Das belegt ein Update einer Phase-3-Studie.
Wird in der Bildgebung inzidentell eine vergrößerte Milz diagnostiziert, stellt sich die Frage nach der Ursache. Ab welcher Größe das Risiko für hämatologische Malignome und Lebererkrankungen steigt, hat ein dänisches Team untersucht.
Forschende aus den USA sind in elektronischen Gesundheitsakten auf einen Zusammenhang von Farbenblindheit und Blasenkarzinomen gestoßen. Was zunächst merkwürdig klingt, lässt sich prinzipiell recht schlüssig erklären …
Das Ausmaß der Myokardischämie und die Schwere der pektanginösen Symptome stehen bei stabiler KHK in keiner engen Beziehung. Warum das so ist, hat eine britische Forschergruppe versucht zu ergründen.
